Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Clofarabine in MDS and CMML
NCT00708721Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Mar 2008
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Utah. Primary endpoints: Number of Participants Who Experienced a Dose-Limiting Toxicity at 28 days and Overall Response Rate at 4 weeks. Started Mar 2008; status: terminated.
02
Drugs
clofarabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00708721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708721.